Skip to main content
N4 PHARMA PLC logo

N4 PHARMA PLC — Investor Relations & Filings

Ticker · N4P ISIN · GB00BYW8QM32 LEI · 213800I841D2RKMFK955 IL Professional, scientific and technical activities
Open in API
Filings indexed 840 across all filing types
Latest filing 2018-06-26 Declaration of Voting R…
Country GB United Kingdom
Listing IL N4P

About N4 PHARMA PLC

https://n4pharma.com/

N4 Pharma PLC is a specialist pharmaceutical company focused on the development of Nuvec®, its proprietary silica nanoparticle delivery system. This platform technology is designed to enhance the cellular delivery and potency of nucleic acid-based treatments, such as vaccines and cancer therapies. The company's primary focus is on applying Nuvec® to enable advanced therapies for oncology and infectious diseases. N4 Pharma's business model involves developing and out-licensing its technology to pharmaceutical and biotechnology partners to improve the performance of new and existing drugs.

Recent filings

Filing Released Lang Actions
Verona Pharma plc : Result of General Meeting of Shareholders
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document explicitly states that it announces the results of the 'General Meeting held today' and provides a table detailing the 'Votes for' and 'Votes against' for specific resolutions (e.g., 'Authority to allot shares'). This content directly corresponds to the official results from a shareholder vote at a general meeting. Therefore, the appropriate classification is Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short (2737 chars), but the content is the result itself, not an announcement *about* the results being published elsewhere, making DVA more specific than RPA or RNS.
2018-06-26 English
Nuvec® Update
Regulatory Filings Classification · 1% confidence The document begins with 'RNS Number : 6683R' and is dated June 18, 2018. It provides an update on the company's Nuvec® program and a collaboration with MedImmune UK, detailing research progress and expected timelines (Q4 2018 results). The text concludes with contact information and a statement: 'This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.' This structure, originating from the RNS service, indicates a general regulatory announcement that does not fit the specific categories like 10-K, ER, or IR. Since it is a general update disseminated via the RNS system and doesn't fit a more specific category (like DIRS, DIV, or MANG), the most appropriate classification is the general regulatory filing fallback.
2018-06-18 English
Hardman & Co Research: Evgen Pharma (EVG): Encouraging interim data from the STEM trial
Regulatory Filings Classification · 1% confidence The document is a short announcement (3928 characters) from 'Hardman & Co Research' regarding 'Evgen Pharma'. It summarizes interim trial data and explicitly states, 'Please click here for the full report:' followed by a PDF link. This structure—a brief summary announcing the availability of a detailed report—fits the definition of a Report Publication Announcement (RPA). It is not the full financial report (10-K or IR) itself, nor is it a standard regulatory filing (RNS) as it is clearly an analyst research note being published/announced.
2018-06-13 English
Full Year Results
Earnings Release Classification · 1% confidence The document is an 'Earnings Release' (ER) for Evgen Pharma PLC. It contains the 'Final Results for the year ended 31 March 2018', highlights of financial performance (loss, cash position), operational updates, and management commentary. While it is a comprehensive summary, it is structured as an initial announcement of annual results rather than the full, audited Annual Report (10-K) document itself, which would typically be a much longer, formal regulatory filing. It follows the standard format for an RNS-distributed earnings release. FY 2018
2018-06-13 English
Second Price Monitoring Extn
Regulatory Filings Classification · 1% confidence The document text contains an 'RNS Number' (9437Q) and explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' The content describes a 'Second Price Monitoring Extension' related to trading activity, which is a type of regulatory market announcement. Since this is a general regulatory announcement that doesn't fit the specific categories like DIV, DIRS, or ER, and it is provided via the RNS service, the most appropriate classification is the general regulatory filing category.
2018-06-11 English
Price Monitoring Extension
Regulatory Filings Classification · 1% confidence The document is very short (1480 characters) and contains an RNS Number ('9431Q') and mentions 'RNS, the news service of the London Stock Exchange'. The content itself is a specific, brief announcement regarding a 'Price Monitoring Extension' for trading, which is a type of market operational update. This does not fit the definitions for formal financial reports (10-K, IR, ER) or specific corporate actions (DIV, CAP, DIRS). Since it is a direct, non-standard regulatory announcement distributed via the RNS system, and it is not a report announcement (RPA), the most appropriate general category is Regulatory Filings (RNS).
2018-06-11 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.